Kairos Pharma Ltd (KAPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,675 | 4,491 | 5,575 | 3,034 | 3,616 |
| Marketable Securities | 625 | 845 | 1,057 | 1,717 | 2,379 |
| TOTAL | $4,443 | $5,387 | $6,656 | $4,839 | $6,050 |
| Non-Current Assets | |||||
| Intangibles | 22 | 62 | 102 | 142 | 182 |
| Other Non-Current Assets | 1,279 | 1,091 | 1,308 | 1,692 | 1,705 |
| TOTAL | $1,301 | $1,153 | $1,410 | $1,834 | $1,887 |
| Total Assets | $5,744 | $6,540 | $8,066 | $6,673 | $7,937 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 431 | 199 | 402 | 676 | 805 |
| TOTAL | $431 | $199 | $402 | $676 | $805 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $431 | $199 | $402 | $676 | $805 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 21,411 | 21,411 | 20,821 | 20,744 | 16,849 |
| Common Shares | 21 | 21 | 21 | 18 | 500 |
| Retained earnings | -15,916 | -14,262 | -12,897 | -11,499 | -10,077 |
| TOTAL | $5,313 | $6,341 | $7,664 | $5,997 | $7,132 |
| Total Liabilities And Equity | $5,744 | $6,540 | $8,066 | $6,673 | $7,937 |